Prostate Cancer Trial, Recruiting NCT07357259 Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna Condition: Prostate Cancer
Back to Prostate Cancer

Prostate Cancer Trial, Recruiting

NCT07357259
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have recently been diagnosed with prostate cancer and are in the process of having their cancer staged (assessed for spread)
  • People whose prostate cancer has shown signs of returning through a rise in PSA blood test levels after previously receiving surgery and/or radiotherapy intended to cure the cancer
  • People with high-risk prostate cancer, meaning their Gleason score (a measure of cancer aggressiveness) is 8 or higher, or their PSA level is 20 ng/mL or higher
  • People who are able and willing to sign a consent form and agree to their personal data being used for the study

Who may not be able to join:

  • People who have bladder, urinary, or other genitourinary conditions that could affect the imaging results or how they are interpreted
  • People whose prostate cancer is classified as low- or intermediate-risk
  • People whose follow-up scan would need to be done on a different PET/CT scanner than the one used for their first scan
  • People who would need an additional PET/CT scan due to poor image quality from issues such as urine retention or excessive movement during the scan
  • People who have previously taken part in this trial and would be returning for a repeat scan as a new visit
  • People who are unable to give informed consent or who have difficulty making decisions for themselves
  • People with a known allergy or sensitivity to the radioactive substance used in the scan or any of its ingredients
  • People for whom a PET/CT scan is not suitable — for example, due to severe claustrophobia, very high body weight, or being unable to remain still and cooperate during the scan

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Michela Moscarino, Technician, IRCCS Università di Bologna, Policlinico di Sant'Orsola

Phone: +390512143179

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Registry
ClinicalTrials.gov
Start date
3 February 2025
Est. completion
1 March 2026

Where this trial is recruiting

🇮🇹 Italy

Primary endpoints

Matching Quality of Delayed PET with Standard CT

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov